Diagnosis, differential diagnosis and treatment of polymyalgia rheumatica

Drugs and Aging

Volumn 23, Issue 5, 2006, Pages 391-402

  Nothnagl, Thomas ^a   Leeb, Burkhard F ^a,b  

^a Centre for Rheumatology   (Austria)

^b Lower Austrian Center for Rheumatology   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; C REACTIVE PROTEIN; CORTICOSTEROID DERIVATIVE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISOLONE; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

BURSITIS; CERVICAL SPONDYLOSIS; CLINICAL FEATURE; CLINICAL TRIAL; CORRELATION ANALYSIS; CORTICOSTEROID THERAPY; DERMATOMYOSITIS; DIABETES MELLITUS; DIAGNOSTIC PROCEDURE; DIFFERENTIAL DIAGNOSIS; DISEASE ACTIVITY; DOSE RESPONSE; DRUG EFFECT; EDEMA; ERYTHROCYTE SEDIMENTATION RATE; EUROPE; FIBROMYALGIA; FROZEN SHOULDER; FUNCTIONAL ASSESSMENT; GIANT CELL ARTERITIS; HUMAN; HYPERTENSION; HYPOTHYROIDISM; IMAGING SYSTEM; INFECTION; LABORATORY TEST; LONG TERM CARE; MEDICAL SOCIETY; MOOD CHANGE; MORBIDITY; MORTALITY; MULTIPLE MYELOMA; MUSCLE STIFFNESS; MUSCLE WEAKNESS; MUSCULOSKELETAL DISEASE; MYOPATHY; OSTEOARTHRITIS; OSTEOPOROSIS; PAIN; PAIN ASSESSMENT; PARKINSON DISEASE; PATHOGENESIS; PATIENT CARE; PATIENT MONITORING; PATIENT SATISFACTION; PELVIC GIRDLE; PHYSICIAN; POLYARTERITIS NODOSA; POLYMYOSITIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; QUESTIONNAIRE; REVIEW; RHEUMATIC POLYMYALGIA; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; RS3 PE SYNDROME; SCORING SYSTEM; SIDE EFFECT; SMALL VESSEL VASCULITIS; SYNOVITIS; SYSTEMIC LUPUS ERYTHEMATOSUS; TENDINITIS; TENDON DISEASE; THYROTOXICOSIS; TREATMENT RESPONSE; TUMOR; WEIGHT GAIN;

AGED; DIAGNOSIS, DIFFERENTIAL; EUROPE; FEMALE; GUIDELINES; GUIDELINES AS TOPIC; HUMANS; LABORATORY TECHNIQUES AND PROCEDURES; MALE; POLYMYALGIA RHEUMATICA; PROGNOSIS;

EID: 33745937665     PISSN: 1170229X     EISSN: 1170229X     Source Type: Journal    
DOI: 10.2165/00002512-200623050-00003     Document Type: Review

References (60)

1. Bruce W. Senile rheumatic gout. Br Med J 1888; 2: 811-3
2. Barber HS. Myalgic syndrome with constitutional effects: polymyalgia rheumatica. Ann Rheum Dis 1957; 16: 230-7
3. Epperly TD, Moore KE, Harrover JD. Polymyalgia rheumatica and temporal arteritis. Fam Physician 2000 Aug 15; 62 (4): 789-96
4. Chuang TY, Hunder GG, Ilstrup DM, et al. Polymyalgia rheumatica: a 10-year epidemiologic and clinical study. Ann Intern Med 1982; 97 (5): 672-80
5. Weyand C, Fulbright JW, Evans JM, et al. Corticosteroid requirements in polymyalgia rheumatica. Arch Intern Med 1999; 22; 159 (6): 577-84
6. Whittaker PE, Fitzsimmons MG. A 24-year-old man with symptoms and signs of polymyalgia rheumatica. J Fam Pract 1998; 47 (1): 68-71
7. Salvarani C, Cantini F, Boiardi L, et al. Polymyalgia rheumatica and giant cell arteritis. N Engl J Med 2002; 347: 261-71
8. Cimmino MA, Zaccaria A. Epidemiology of polymyalgia rheumatica. Clin Exp Rheumatol 2000; 18 (4 Suppl. 20): S9-11
9. Peris P. Polymyalgia rheumatica is not seasonal in pattern and is unrelated to parvovirus b19 infection. J Rheumatol 2003; 30 (12): 2624-6
10. Wagner AD, Gerard HC, Fresemann T, et al. Detection of Chlamydia pneumoniae in giant cell vasculitis and correlation with the topographic arrangement of tissue-infiltrating dendritic cells. Arthritis Rheum 2000; 43 (7): 1543-51
11. Gonzalez-Gay MA. Giant cell arteritis and polymyalgia rheumatica: two different but often overlapping conditions. Semin Arthritis Rheum 2004; 33 (5): 289-93
12. Gabriel SE, O'Fallon MW, Achkar AA, et al. The use of clinical characteristics to predict the results of temporal artery biopsy among patients with suspected giant cell arteritis. J Rheumatol 1995; 22: 93-6
13. Evans JM, Hunder GG. Polymyalgia rheumatica and giant cell arteritis. Rheum Dis Clin North Am 2000; 26 (3): 493-515
14. Cantini F, Niccoli L, Storri L, et al. Are polymyalgia rheumatica and giant cell arteritis the same disease? Semin Arthritis Rheum 2004; 33 (5): 294-301
15. Weyand CM, Goronzy JJ. Arterial wall injury in giant cell arteritis. Arthritis Rheum 1999; 42: 844-53
16. Martinez-Taboda VM, Bartolome MJ, Lopez-Hoyos M, et al. HLA-DRB1 allele distribution in polymyalgia rheumatica and giant cell arteritis: influence on clinical subgroups and prognosis. Semin Arthritis Rheum 2004; 34 (1): 454-64
17. Weyand CM, Hicok KC, Hunder GG, et al. Tissue cytokine patterns in patients with polymyalgia rheumatica and giant cell arteritis. Ann Intern Med 1994; 121: 484-91
18. Cantini F, Niccoli L, Nannini C, et al. Inflammatory changes of hip synovial structures in polymyalgia rheumatica. Clin Exp Rheumatol 2005; 23 (4): 462-8
19. Frediani B, Falsetti P, Storri L, et al. Evidence for synovitis in active polymyalgia rheumatica: sonographic study in a large series of patients. J Rheumatol 2002; 29 (1): 123-30
20. Narvaez J, Nolla-Sole JM, Narvaez JA, et al. Musculoskeletal manifestations in polymyalgia rheumatica and temporal arteritis. Ann Rheum Dis 2001; 60 (11): 1060-3
21. Salvarani C, Cantini F, Boiardi L, et al. Polymyalgia rheumatica. Best Pract Res Clin Rheumatol 2004; 18 (5): 705-22
22. Salvarani C, Hunder GG. Musculoskeletal manifestations in a population-based cohort of patients with giant cell arteritis. Arthritis Rheum 1999 Jun; 42 (6): 1259-66
23. Proven A, Gabriel SE, O'Fallon WM, et al. Polymyalgia rheumatica with low erythrocyte sedimentation rate at diagnosis. J Rheumatol 1999; 26 (6): 1333-7
24. Gonzalez-Gay MA, Rodriguez-Valverde V, Blanco R, et al. Polymyalgia rheumatica without significantly increased erythrocyte sedimentation rate: a more benign syndrome. Arch Intern Med 1997 Feb 10; 157 (3): 317-20
25. Corrigall VM, Dolan AL, Dasgupta B, et al. The sequential analysis of T lymphocyte subsets and interleukin-6 in polymyalgia rheumatica patients as predictors of disease remission and steroid withdrawal. Br J Rheumatol 1997; 36 (9): 976-80
26. Narvaez J, Narvaez JA, Nolla JM, et al. Giant cell arteritis and polymyalgia rheumatica: usefulness of vascular magnetic resonance imaging studies in the diagnosis of aortitis. Rheumatology. Epub 2005 Feb 16
27. Walter MA, Melzer RA, Schindler C, et al. The value of [(18)F]FDG-PET in the diagnosis of large vessel vasculitis and the assessment of activity and extent of disease. Eur J Nucl Med Mol Imaging. Epub 2005 Mar 4
28. Leeb BF. Disease activity assessment in polymyalgia rheumatica (PMR) and giant cell arteritis (GCA). Rheumatology 2005; 44 Suppl. 3: iii5-6
29. Bird HA, Esselinckx W, Dixon AS, et al. An evaluation of criteria for polymyalgia rheumatica. Ann Rheum Dis 1979; 38: 434-9
30. Jones JG, Hazleman BL. Prognosis and management of polymyalgia rheumatica. Ann Rheum Dis 1981; 40: 1-5
31. Wilke WS, Wysenbeek AJ, Krall PL, et al. Masked presentation of giant-cell arteritis. Cleve Clin Q 1985; 52 (2): 155-9
32. Nobunaga M, Yoshioka K, Yasuda M, et al. Clinical studies of polymyalgia rheumatica: a proposal of diagnostic criteria. Jpn J Med 1989; 28: 452-6
33. Nothnagl T, Leeb BF. Polymyalgia rheumatica - ein klinischer Überlick. J Miner Stoffwechs 2004; 11: 37-9
34. Bird HA, Leeb BF, Montecucco CM, et al. A comparison of the sensitivity of diagnostic criteria for polymyalgia rheumatica. Ann Rheum Dis 2005; 64 (4): 626-9
35. Leeb BF, Bird HA, Nesher G, et al. EULAR response criteria for polymyalgia rheumatica: results of an initiative of the European collaborating Polymyalgia Rheumatica group (Subcommittee of ESCISIT [EULAR Standing Committee on Clinical Trials Including Therapeutical Trials]). Ann Rheum Dis 2003; 62: 1189-94
36. Weyand C, Fulbright JW, Evans JM, et al. Corticosteroid requirements in polymyalgia rheumatica. Arch Intern Med 1999 Mar 22; 159 (6): 577-84;
37. Wolfe F, Smythe HA, Yunus MB, et al. The American College of Rheumatology 1990 criteria for the classification of fibromyalgia. Report of the Multicenter Criteria Committee. Arthritis Rheum 1990; 33: 160-72
38. Mertens JC, Willemsen G, Van Saase JL, et al. Polymyalgia rheumatica and temporal arteritis: a retrospective study of 111 patients. Clin Rheumatol 1995 Nov; 14 (6): 650-5
39. Little MA, Nazar L, Farrington K. Polymyalgia rheumatica preceding small-vessel vasculitis: changed spots or misdiagnosis? QJM 2004 May; 97 (5): 289-92
40. McCarty DJ, O'Duffy JD, Pearson L, et al. Remitting seronegative symmetrical synovitis with pitting edema. RS3PE syndrome. JAMA 1985 Nov 15; 254 (19): 2763-7
41. Arima K, Origuchi T, Tamai M, et al. RS3PE syndrome presenting as vascular endothelial growth factor associated disorder. Ann Rheum Dis 2005 Nov; 64 (11): 1653-5
42. Leeb BF. Corticosteroids in Polymyalgia Rheumatica (PMR). The CODIS-trial. Ann Rheum Dis 2005 (Suppl. III); 16; (SP 0051); EULAR 2005 Vienna
43. Leeb BF, Bird HA. A disease activity score for polymyalgia rheumatica -PMR-AS. Ann Rheum Dis 2004; 63: 1279-83
44. Cantini F, Salvarani C, Olivieri I, et al. Erythrocyte sedimentation rate and C-reactive protein in the evaluation of disease activity and severity in polymyalgia rheumatica: a prospective follow-up study. Semin Arthritis Rheum 2000; 30 (1): 17-24
45. Lestico MR, Boh LE, Schuna AA. Polymyalgia rheumatica. Clin Pharm 1993; 12 (8): 571-80
46. Topol EJ. Arthritis medicines and cardiovascular events: 'house of coxibs'. JAMA 2005; 293 (3): 366-8
47. Feinberg HL, Sherman JD, Schrepferman CG, et al. The use of methotrexate in polymyalgia rheumatica. J Rheumatol 1996; 23 (9): 1550-2
48. Ferraccioli G, Salaffi F, De Vita S, et al. Methotrexate in polymyalgia rheumatica: preliminary results of an open, randomized study. J Rheumatol 1996; 23 (4): 624-8
49. De Silva M, Hazleman BL. Azathioprine in giant cell arteritis/polymyalgia rheumatica: a double-blind study. Ann Rheum Dis 1986; 45 (2): 136-8
50. Salvarani C, Cantini F, Niccoli L, et al. Treatment of refractory polymyalgia rheumatica with infliximab: a pilot study. J Rheumatol 2003; 30 (4): 760-3
51. Gabriel SE, Sunku J, Salvarani C, et al. Adverse outcomes of antiinflammatory therapy among patients with polymyalgia rheumatica. Arthritis Rheum 1997; 40 (10): 1873-8
52. Panthakalam S, Bhatnagar D, Klimiuk P. The prevalence and management of hyperglycaemia in patients with rheumatoid arthritis on corticosteroid therapy. Scott Med J 2004; 49 (4): 139-41
53. Feldstein AC, Elmer PJ, Nichols GA, et al. Practice patterns in patients at risk for glucocorticoid-induced osteoporosis. Osteoporos Int 2005; 16 (12): 2168-74
54. Lodder MC, de Jong Z, Kostense PJ, et al. Bone mineral density in patients with rheumatoid arthritis: relation between disease severity and low bone mineral density. Ann Rheum Dis 2004; 63 (12): 1576-80
55. Nurmohamed MT, van Halm VP, Dijkmans BA. Cardiovascular risk profile of antirheumatic agents in patients with osteoarthritis and rheumatoid arthritis. Drugs 2002; 62 (11): 1599-609
56. Svoboda T, Andel I, Burgschmidt I, et al. A corticosteroid side effect questionnaire discriminates between corticosteroid using and not-using patients with rheumatoid arthritis (RA) and polymyalgia rheumatica (PMR). Ann Rheum Dis 2004 Suppl. 1: 174 (THU 0221); EULAR 2004, Berlin
57. Felson DT, Anderson JJ, Boers M, et al. The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. Arthritis Rheum 1993; 36: 729-40
58. Furst DE, Breedveld FC, Kalden JR, et al. Updated consensus statement on biological agents for the treatment of rheumatoid arthritis and other rheumatic diseases (May 2002). Ann Rheum Dis 2001; 61 Suppl. II: ii2-7
59. Maktari A, Andel I, Svoboda T, et al. The polymyalgia rheumatica disease activity score (PMR-AS) in daily practice. Ann Rheum Dis 2004 (Suppl. 1): 313 (FRI 0210); EULAR 2004, Berlin
60. Streiner DL. Starting at the beginning: an introduction to coefficient alpha and internal consistency. J Pers Assess 2003; 80 (1): 99-103